Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Wins Genentech, But Will Biotech Employees Remain?

Executive Summary

After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake
Advertisement

Related Content

EMA Looks At Avastin, As Novartis/Roche Appeal Italian Competition Fines
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Roche Blinks But Is $93 Enough For Genentech Shareholders?
Roche's Acquisition of Genentech: Retention Program Unlikely to Stem Departures
Genentech/Roche: The End Of An Era
Genentech/Roche: The End Of An Era

Topics

Advertisement
UsernamePublicRestriction

Register

PS050821

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel